Gene Therapy R&D Market Report 2024-2034

Overall world revenue for Gene Therapy R&D Market, 2024 to 2034 in terms of value the market will surpass US$3,600 million in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Gene Therapy R&D Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments, and a Promising Pipeline Reshaping Medicine's Future

In the past five years, gene therapy has made a remarkable comeback. Advancements in virology, vector and capsid architecture, and manufacturing have led to exciting breakthroughs and regulatory progress, capturing the attention of biotech investors. Biopharma firms are strategizing to gain an edge, expanding facilities, forming partnerships, and collaborating with contract manufacturing organizations (CMOs).

According to a recent report by the Alliance for Regenerative Medicine, over 1,400 global companies are focused on cell and gene therapies (CGTs), with 3,500 therapies in development and over 2,000 active clinical trials. North America leads in clinical trials, followed by the Asia Pacific and Europe, with oncology and rare diseases as the primary therapeutic targets. Venture capital remains the main driver of growth, reflecting enthusiasm for scientific advancements and potential treatment breakthroughs.

The FDA expects to receive over 200 investigational new drug applications for CGTs annually, approving 10 to 20 new therapies per year. In 2024, up to 21 cell therapy and 31 gene therapy launches are anticipated, prompting the FDA to elevate its Office of Tissues and Advanced Therapies (OTAT) within the Center for Biologics Research and Evaluation (CBER). Proposed structural changes aim to enhance review capabilities and expertise to accommodate the growing workload and ensure efficient regulatory processes.

Key Questions Answered

How is the gene therapy R&D market evolving?
What is driving and restraining the gene therapy R&D market?
How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each gene therapy R&D submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the gene therapy R&D projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of gene therapy R&D projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the gene therapy R&D market today, and over the next 10 years:

This 340-page report provides 156 tables and 192 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the gene therapy R&D market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Disease

Cancer
Rare Diseases
Oncologic
Non-oncologic
Cardiovascular Diseases
Ophthalmic Diseases
Haematology
Neurological
Diabetes Mellitus
Other Diseases

Vector

Viral
Retrovirus
Adenovirus
AAV
Lentivirus
Others
Non-viral
Naked DNA
Gene Gun
Electroporation
Lipofection

Techniques

Gene Augmentation Therapy
Gene Replacement Therapy

Participants

Small/Medium Pharma & Biotech
Universities & Research Institutes
Hospitals
Government & Public Bodies
Big Pharma

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

The report also includes profiles and for some of the leading companies in the Gene Therapy R&D Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

American Gene Technologies
Applied Genetic
Astellas Pharma Inc.
Bayer
Benitec BioPharma
Biogen
Bluebird Bio
Bristol Myers Squibb
Calimmune, Inc. (CSL Behiring)
Cellectis
GeneQuine Biotherapeutics
GenSight Biologics
Gilead Lifesciences, Inc.
Novartis AG
Ocugen, Inc.
Orchard Therapeutics
Oxford Biomedica
Pfizer, Inc.
REGENXBIO Inc.
Sangamo Therapeutics, Inc.
Sanofi
Sarepta Therapeutics, Inc.
Spark Therapeutics (Subsidiary of Roche)
Takeda Pharmaceuticals
Taysha GTx
Transgene
UniQure N. V.
ViGeneron
Voyager Therapeutics

How will the Gene Therapy R&D Market, 2024 to 2034 report help you?

In summary, the 340-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Gene Therapy R&D Market 2024 to 2034, with forecasts for disease, vector, techniques, and participants, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 22 key national markets - See forecasts for the Gene Therapy R&D Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 29 of the major companies involved in the Gene Therapy R&D Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Gene Therapy R&D Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Gene Therapy R&D Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Robust Gene Therapy Pipeline to Boost Growth
3.2.1.2 Technological Advancements to Fuel Market Growth
3.2.1.3 Increasing Financing and Acquisitions by Major Players
3.2.1.4 Growing Prevalence of Targeted Diseases Treatment
3.2.2 Market Restraining Factors
3.2.2.1 Cell & Gene Therapies Target Specific Diseases
3.2.2.2 High Cost to Stifle Gene Therapy R&D Growth
3.2.2.3 Regulatory Scenarios to Challenge Industry Growth
3.2.3 Market Opportunities
3.2.3.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
3.2.3.2 Facility Expansion Anticipated to Offer Lucrative Growth Prospects
3.2.3.3 Artificial Intelligence Can Bring Value to Gene Therapy R&D
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat of Substitute Products
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors Impacting Gene Therapy R&D Market
3.5.2 Economic Factors Impacting Gene Therapy R&D Market
3.5.3 Social Factors Impacting Gene Therapy R&D Market
3.5.4 Technological Factors Impacting Gene Therapy R&D Market

4 Gene Therapy R&D Market Analysis by Disease

4.1 Key Findings
4.2 Disease Segment: Market Attractiveness Index
4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease
4.4 Cancer
4.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Rare Diseases
4.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Cardiovascular Diseases
4.6.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.6.2 Market Share by Region, 2024 & 2034 (%)
4.7 Ophthalmic Diseases
4.7.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.7.2 Market Share by Region, 2024 & 2034 (%)
4.8 Hematology
4.8.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.8.2 Market Share by Region, 2024 & 2034 (%)
4.9 Neurological
4.9.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.9.2 Market Share by Region, 2024 & 2034 (%)
4.10 Diabetes Mellitus
4.10.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.10.2 Market Share by Region, 2024 & 2034 (%)
4.11 Other Diseases
4.11.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
4.11.2 Market Share by Region, 2024 & 2034 (%)

5 Gene Therapy R&D Market Analysis by Vector

5.1 Key Findings
5.2 Vector Segment: Market Attractiveness Index
5.3 Gene Therapy R&D Market Size Estimation and Forecast by Vector
5.4 Viral
5.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Non-viral
5.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Gene Therapy R&D Market Analysis by Techniques

6.1 Key Findings
6.2 Techniques Segment: Market Attractiveness Index
6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques
6.4 Gene Augmentation Therapy
6.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Gene Replacement Therapy
6.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Gene Therapy R&D Market Analysis by Participants

7.1 Key Findings
7.2 Participants Segment: Market Attractiveness Index
7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants
7.4 Small/Medium Pharma & Biotech
7.4.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Universities & Research Institutes
7.5.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Hospitals, Government & Public Bodies
7.6.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Big Pharma
7.7.1 Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Gene Therapy R&D Market Analysis by Region

8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Gene Therapy R&D Market Analysis

9.1 Key Findings
9.2 North America Gene Therapy R&D Market Attractiveness Index
9.3 North America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Gene Therapy R&D Market Size Estimation and Forecast by Country
9.5 North America Gene Therapy R&D Market Size Estimation and Forecast by Disease
9.6 North America Gene Therapy R&D Market Size Estimation and Forecast by Vector
9.7 North America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
9.8 North America Gene Therapy R&D Market Size Estimation and Forecast by Participants
9.9 U.S. Gene Therapy R&D Market Analysis
9.10 Canada Gene Therapy R&D Market Analysis

10 Europe Gene Therapy R&D Market Analysis

10.1 Key Findings
10.2 Europe Gene Therapy R&D Market Attractiveness Index
10.3 Europe Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Europe Gene Therapy R&D Market Size Estimation and Forecast by Country
10.5 Europe Gene Therapy R&D Market Size Estimation and Forecast by Disease
10.6 Europe Gene Therapy R&D Market Size Estimation and Forecast by Vector
10.7 Europe Gene Therapy R&D Market Size Estimation and Forecast by Techniques
10.8 Europe Gene Therapy R&D Market Size Estimation and Forecast by Participants
10.9 Germany Gene Therapy R&D Market Analysis
10.10 UK Gene Therapy R&D Market Analysis
10.11 France Gene Therapy R&D Market Analysis
10.12 Italy Gene Therapy R&D Market Analysis
10.13 Spain Gene Therapy R&D Market Analysis
10.14 Russia Gene Therapy R&D Market Analysis
10.15 Rest of Europe Gene Therapy R&D Market Analysis

11 Asia Pacific Gene Therapy R&D Market Analysis

11.1 Key Findings
11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index
11.3 Asia Pacific Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Country
11.5 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Disease
11.6 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Vector
11.7 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Techniques
11.8 Asia Pacific Gene Therapy R&D Market Size Estimation and Forecast by Participants
11.9 Japan Gene Therapy R&D Market Analysis
11.10 China Gene Therapy R&D Market Analysis
11.11 India Gene Therapy R&D Market Analysis
11.12 Australia Gene Therapy R&D Market Analysis
11.13 South Korea Gene Therapy R&D Market Analysis
11.14 South East Asia Gene Therapy R&D Market Analysis
11.15 Rest of Asia Pacific Gene Therapy R&D Market Analysis

12 Latin America Gene Therapy R&D Market Analysis

12.1 Key Findings
12.2 Latin America Gene Therapy R&D Market Attractiveness Index
12.3 Latin America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Country
12.5 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Disease
12.6 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Vector
12.7 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Techniques
12.8 Latin America Gene Therapy R&D Market Size Estimation and Forecast by Participants
12.9 Brazil Gene Therapy R&D Market Analysis
12.10 Mexico Gene Therapy R&D Market Analysis
12.11 Rest of Latin America Gene Therapy R&D Market Analysis

13 MEA Gene Therapy R&D Market Analysis

13.1 Key Findings
13.2 MEA Gene Therapy R&D Market Attractiveness Index
13.3 MEA Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 MEA Gene Therapy R&D Market Size Estimation and Forecast by Country
13.5 MEA Gene Therapy R&D Market Size Estimation and Forecast by Disease
13.6 MEA Gene Therapy R&D Market Size Estimation and Forecast by Vector
13.7 MEA Gene Therapy R&D Market Size Estimation and Forecast by Techniques
13.8 MEA Gene Therapy R&D Market Size Estimation and Forecast by Participants
13.9 GCC Gene Therapy R&D Market Analysis
13.10 South Africa Gene Therapy R&D Market Analysis
13.11 Rest of MEA Gene Therapy R&D Market Analysis

14 Company Profiles

14.1 Astellas Pharma Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2015-2023
14.1.3.2 Regional Market Shares, 2022
14.1.3.3 R&D, 2015-2023
14.1.4 Product Benchmarking
14.2 American Gene Technologies
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.3 Beacon Therapeutics
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2022
14.3.3.2 R&D, 2015-2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Bayer
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2015-2023
14.4.3.2 Regional Market Shares, 2023
14.4.3.3 Business Segment Market Shares, 2023
14.4.3.4 R&D, 2015-2023
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 Benitec BioPharma
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2015-2023
14.5.3.2 R&D, 2015-2023
14.5.4 Product Benchmarking
14.6 Biogen
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2015-2023
14.6.3.2 Regional Market Shares, 2022
14.6.3.3 R&D, 2015-2023
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Bluebird Bio
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2015-2023
14.7.3.2 R&D, 2015-2023
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.8 Bristol Myers Squibb
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2015-2023
14.8.3.2 Regional Market Shares, 2023
14.8.3.3 R&D, 2015-2023
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Calimmune, Inc. (CSL Behiring)
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Strategic Outlook
14.10 Cellectis
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2015-2023
14.10.3.2 R&D, 2015-2023
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 GenSight Biologics
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.12 Gilead Lifesciences, Inc.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2015-2023
14.12.3.2 R&D, 2015-2023
14.12.4 Product Benchmarking
14.13 Novartis AG
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2015-2023
14.13.3.2 Regional Market Shares, 2023
14.13.3.3 Business Segment Market Shares, 2023
14.13.3.4 R&D, 2015-2023
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Orchard Therapeutics
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.15 Oxford Biomedica
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2023
14.15.3.2 Regional Market Shares, 2023
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Pfizer, Inc.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2015-2023
14.16.3.2 Regional Market Shares, 2023
14.16.3.3 Business Segment Market Shares, 2023
14.16.3.4 R&D, 2015-2023
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 REGENXBIO Inc.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2015-2023
14.17.3.2 R&D, 2015-2023
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Sangamo Therapeutics, Inc.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.3.1 Net Revenue, 2015-2023
14.18.3.2 R&D, 2015-2023
14.18.4 Product Benchmarking
14.18.5 Strategic Outlook
14.19 Sanofi
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2015-2023
14.19.3.2 Regional Market Shares, 2023
14.19.3.3 R&D, 2015-2023
14.19.4 Product Benchmarking
14.19.5 Strategic Outlook
14.20 Spark Therapeutics (Subsidiary of Roche)
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Product Benchmarking
14.20.4 Strategic Outlook
14.21 Takeda Pharmaceuticals
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.3.1 Net Revenue, 2015-2023
14.21.3.2 R&D, 2015-2023
14.21.4 Product Benchmarking
14.21.5 Strategic Outlook
14.22 Transgene
14.22.1 Company Snapshot
14.22.2 Company Overview
14.22.3 Product Benchmarking
14.23 UniQure NV
14.23.1 Company Snapshot
14.23.2 Company Overview
14.23.3 Financial Analysis
14.23.3.1 Net Revenue, 2015-2023
14.23.3.2 R&D, 2015-2023
14.23.4 Product Benchmarking
14.23.5 Strategic Outlook
14.24 Voyager Therapeutics
14.24.1 Company Snapshot
14.24.2 Company Overview
14.24.3 Financial Analysis
14.24.3.1 Net Revenue, 2015-2023
14.24.3.2 R&D, 2015-2023
14.24.4 Product Benchmarking
14.24.5 Strategic Outlook
14.25 ViGeneron
14.25.1 Company Snapshot
14.25.2 Company Overview
14.25.3 Product Benchmarking
14.25.4 Strategic Outlook
14.26 GQ Bio Therapeutics GmbH
14.26.1 Company Snapshot
14.26.2 Company Overview
14.26.3 Product Benchmarking
14.26.4 Strategic Outlook
14.27 OCUGEN, INC.
14.27.1 Company Snapshot
14.27.2 Company Overview
14.27.3 Product Benchmarking
14.27.4 Strategic Outlook
14.28 Taysha GTx
14.28.1 Company Snapshot
14.28.2 Company Overview
14.28.3 Product Benchmarking
14.29 Sarepta Therapeutics, Inc.
14.29.1 Company Snapshot
14.29.2 Company Overview
14.29.3 Product Benchmarking
14.29.4 Strategic Outlook

15 Conclusion and Recommendations

15.1 Concluding Remarks
15.2 Recommendations for Market Players

List of Tables

Table 1 Cell and Gene Therapy Landscape
Table 2 Gene Therapy R&D Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 3 Cell and Gene Therapy Landscape
Table 4 Cell and Gene Therapy Landscape
Table 5 Cell and Gene Therapy Landscape
Table 6 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "V" Shaped Recovery
Table 7 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "U" Shaped Recovery
Table 8 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "W" Shaped Recovery
Table 9 Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %): "L" Shaped Recovery
Table 10 Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 11 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 12 Rare Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 13 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 14 Ophthalmic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 15 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 16 Neurological Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 17 Diabetes Mellitus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 18 Other Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 19 Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 20 Pharmaceutical & Biotechnology Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 21 Non-viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 22 Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 23 Gene Augmentation Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 24 Gene Replacement Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 25 Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 26 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Universities Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Big Pharma Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Global Gene Therapy R&D Market Forecast by Region, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 31 North America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 32 North America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 33 North America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 34 North America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 35 North America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 36 U.S. Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 37 Canada Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 38 Europe Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 39 Europe Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 40 Europe Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 41 Europe Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 42 Europe Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 43 Germany Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 44 UK Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 45 France Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 46 Italy Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 47 Spain Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 48 Russia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 49 Rest of Europe Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 50 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 51 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 52 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 53 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 54 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 55 Japan Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 56 China Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 57 India Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 58 Australia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 59 South Korea Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 60 South East Asia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 61 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 62 Latin America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 63 Latin America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 64 Latin America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 65 Latin America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 66 Latin America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 67 Brazil Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 68 Mexico Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 69 Rest of Latin America Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 70 MEA Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 71 MEA Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 72 MEA Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 73 MEA Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 74 MEA Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 75 GCC Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 76 South Africa Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 77 Rest of MEA Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %, CAGR %)
Table 78 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Astellas Pharma Inc.: Product Benchmarking
Table 80 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 American Gene Technologies: Product Benchmarking
Table 82 Beacon Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 Beacon Therapeutics: Product Benchmarking
Table 84 Beacon Therapeutics: Strategic Outlook
Table 85 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Bayer: Product Benchmarking
Table 87 Bayer: Strategic Outlook
Table 88 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Benitec BioPharma: Product Benchmarking
Table 90 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Biogen: Product Benchmarking
Table 92 Biogen: Strategic Outlook
Table 93 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Bluebird Bio: Product Benchmarking
Table 95 Bluebird Bio: Strategic Outlook
Table 96 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Bristol Myers Squibb: Product Benchmarking
Table 98 Bristol Myers Squibb: Strategic Outlook
Table 99 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Calimmune, Inc. (CSL Behiring): Product Benchmarking
Table 101 Calimmune, Inc. (CSL Behiring): Strategic Outlook
Table 102 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Cellectis: Product Benchmarking
Table 104 Cellectis: Strategic Outlook
Table 105 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 GenSight Biologics: Product Benchmarking
Table 107 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Gilead Lifesciences, Inc.: Product Benchmarking
Table 109 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Novartis AG: Product Benchmarking
Table 111 Novartis AG: Strategic Outlook
Table 112 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Orchard Therapeutics: Product Benchmarking
Table 114 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Oxford Biomedica: Product Benchmarking
Table 116 Oxford Biomedica: Strategic Outlook
Table 117 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Pfizer, Inc.: Product Benchmarking
Table 119 Pfizer, Inc.: Strategic Outlook
Table 120 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 REGENXBIO Inc.: Product Benchmarking
Table 122 REGENXBIO Inc.: Strategic Outlook
Table 123 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Sangamo Therapeutics, Inc.: Product Benchmarking
Table 125 Sangamo Therapeutics, Inc.: Strategic Outlook
Table 126 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Sanofi: Product Benchmarking
Table 128 Sanofi: Strategic Outlook
Table 129 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking
Table 131 Spark Therapeutics (Subsidiary of Roche): Strategic Outlook
Table 132 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Takeda Pharmaceuticals: Product Benchmarking
Table 134 Takeda Pharmaceuticals: Strategic Outlook
Table 135 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Transgene: Product Benchmarking
Table 137 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 138 UniQure NV: Product Benchmarking
Table 139 UniQure NV: Strategic Outlook
Table 140 Voyager Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Voyager Therapeutics: Product Benchmarking
Table 142 Voyager Therapeutics: Strategic Outlook
Table 143 ViGeneron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 144 ViGeneron: Product Benchmarking
Table 145 ViGeneron: Strategic Outlook
Table 146 GQ Bio Therapeutics GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 147 GQ Bio Therapeutics GmbH: Product Benchmarking
Table 148 GQ Bio Therapeutics GmbH: Strategic Outlook
Table 149 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 OCUGEN, INC.: Product Benchmarking
Table 151 OCUGEN, INC.: Strategic Outlook
Table 152 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 Taysha GTx: Product Benchmarking
Table 154 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 156 Sarepta Therapeutics, Inc.: Strategic Outlook

List of Figures

Figure 1 Gene Therapy R&D Market Segmentation
Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index
Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index
Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index
Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index
Figure 6 Gene Therapy R&D Market Attractiveness Index by Region
Figure 7 Gene Therapy R&D Market: Market Dynamics
Figure 8 Number of Therapies from Preclinical Through Pre-registration till January 2024
Figure 9 Total Number of Deals by Type
Figure 10 Volume and Dollar Value of Series A and Seed Financings for Gene, Cell, & RNA Therapy Companies
Figure 11 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 12 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 13 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 14 Gene Therapy R&D Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 15 Gene Therapy R&D Market: Porter’s Five Forces Analysis
Figure 16 Gene Therapy R&D Market: PEST Analysis
Figure 17 Gene Therapy R&D Market Attractiveness Index by Disease
Figure 18 Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 19 Gene Therapy R&D Market Share Forecast by Disease, 2024, 2029, 2034 (%)
Figure 20 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 21 Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Rare Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 23 Rare Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 Cardiovascular Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Ophthalmic Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Ophthalmic Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Hematology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Neurological Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 31 Neurological Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Diabetes Mellitus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 Diabetes Mellitus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 34 Other Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 35 Other Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Gene Therapy R&D Market Attractiveness Index by Disease
Figure 37 Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 38 Gene Therapy R&D Market Share Forecast by Vector, 2024, 2029, 2034 (%)
Figure 39 Viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 40 Viral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Non-viral Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 42 Non-viral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Gene Therapy R&D Market Attractiveness Index by Techniques
Figure 44 Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 45 Gene Therapy R&D Market Share Forecast by Techniques, 2024, 2029, 2034 (%)
Figure 46 Gene Augmentation Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 47 Gene Augmentation Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Gene Replacement Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 49 Gene Replacement Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Gene Therapy R&D Market Attractiveness Index by Participants
Figure 51 Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 52 Gene Therapy R&D Market Share Forecast by Participants, 2024, 2029, 2034 (%)
Figure 53 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 54 Small/Medium Pharma & Biotech Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Universities & Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 Universities & Research Institutes Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 57 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 58 Hospitals, Government & Public Bodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 59 Big Pharma Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 60 Big Pharma Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 61 Gene Therapy R&D Market Forecast by Region 2024, 2029, 2034 (Revenue, CAGR%)
Figure 62 Gene Therapy R&D Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 63 Gene Therapy R&D Market by Region, 2024-2034 (US$ Mn)
Figure 64 North America Gene Therapy R&D Market Attractiveness Index
Figure 65 North America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 66 North America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 67 North America Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 68 North America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 69 North America Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 70 North America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 71 North America Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 72 North America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 73 North America Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 74 North America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 75 North America Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 76 U.S. Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 77 Canada Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 78 Europe Gene Therapy R&D Market Attractiveness Index
Figure 79 Europe Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 80 Europe Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 81 Europe Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 82 Europe Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 83 Europe Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 84 Europe Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 85 Europe Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 86 Europe Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 87 Europe Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 88 Europe Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 89 Europe Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 90 Germany Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 91 UK Fund Raising to 31st October 2023
Figure 92 UK Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 93 France Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 94 Italy Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 95 Spain Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 96 Russia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 97 Rest of Europe Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 98 Asia Pacific Gene Therapy R&D Market Attractiveness Index
Figure 99 Asia Pacific Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 100 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 101 Asia Pacific Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 102 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 103 Asia Pacific Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 104 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 105 Asia Pacific Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 106 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 107 Asia Pacific Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 108 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 109 Asia Pacific Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 110 Japan Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 111 China Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 112 India Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 113 Australia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 114 South Korea Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 115 South East Asia Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 116 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 117 Latin America Gene Therapy R&D Market Attractiveness Index
Figure 118 Latin America Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 119 Latin America Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 120 Latin America Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 121 Latin America Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 122 Latin America Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 123 Latin America Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 124 Latin America Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 125 Latin America Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 126 Latin America Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 127 Latin America Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 128 Latin America Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 129 Brazil Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 130 Mexico Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 131 Rest of Latin America Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 132 MEA Gene Therapy R&D Market Attractiveness Index
Figure 133 MEA Gene Therapy R&D Market by Country, 2024, 2029 & 2034 (US$ Million)
Figure 134 MEA Gene Therapy R&D Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 135 MEA Gene Therapy R&D Market Share Forecast by Country, 2024 & 2034 (%)
Figure 136 MEA Gene Therapy R&D Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 137 MEA Gene Therapy R&D Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 138 MEA Gene Therapy R&D Market Forecast by Vector, 2024-2034 (US$ Million, AGR %)
Figure 139 MEA Gene Therapy R&D Market Share Forecast by Vector, 2024 & 2034 (%)
Figure 140 MEA Gene Therapy R&D Market Forecast by Techniques, 2024-2034 (US$ Million, AGR %)
Figure 141 MEA Gene Therapy R&D Market Share Forecast by Techniques, 2024 & 2034 (%)
Figure 142 MEA Gene Therapy R&D Market Forecast by Participants, 2024-2034 (US$ Million, AGR %)
Figure 143 MEA Gene Therapy R&D Market Share Forecast by Participants, 2024 & 2034 (%)
Figure 144 GCC Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 145 South Africa Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 146 Rest of MEA Gene Therapy R&D Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 147 Astellas Pharma Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 148 Astellas Pharma Inc.: Regional Market Shares (%), 2022
Figure 149 Astellas Pharma Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 150 Beacon Therapeutics: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 151 Beacon Therapeutics: R&D, 2015-2022 (US$ Million, AGR %)
Figure 152 Bayer: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 153 Bayer: Regional Market Shares (%), 2023
Figure 154 Bayer: Business Segment Market Shares, 2023
Figure 155 Bayer: R&D, 2015-2023 (US$ million, AGR %)
Figure 156 Benitec BioPharma: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 157 Benitec BioPharma: R&D, 2015-2023 (US$ Million, AGR %)
Figure 158 Biogen: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 159 Biogen: Regional Market Shares (%), 2022
Figure 160 Biogen: R&D, 2015-2023 (US$ Million, AGR %)
Figure 161 Bluebird Bio: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 162 Bluebird Bio: R&D, 2015-2023 (US$ Million, AGR %)
Figure 163 Bristol Myers Squibb: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 164 Bristol Myers Squibb: Regional Market Shares (%), 2023
Figure 165 Bristol Myers Squibb: R&D, 2015-2023 (US$ Million, AGR %)
Figure 166 Cellectis: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 167 Cellectis: R&D, 2015-2023 (US$ Million, AGR %)
Figure 168 Gilead Lifesciences, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 169 Gilead Lifesciences, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 170 Novartis AG: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 171 Novartis AG: Regional Market Shares (%), 2023
Figure 172 Novartis AG: Business Segment Market Shares, 2023
Figure 173 Novartis AG: R&D, 2015-2023 (US$ million, AGR %)
Figure 174 Oxford Biomedica: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 175 Oxford Biomedica: Regional Market Shares (%), 2023
Figure 176 Pfizer, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 177 Pfizer, Inc.: Regional Market Shares (%), 2023
Figure 178 Pfizer, Inc.: Business Segment Market Shares, 2023
Figure 179 Pfizer, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 180 REGENXBIO Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 181 REGENXBIO Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 182 Sangamo Therapeutics, Inc.: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 183 Sangamo Therapeutics, Inc.: R&D, 2015-2023 (US$ Million, AGR %)
Figure 184 Sanofi: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 185 Sanofi: Regional Market Shares (%), 2023
Figure 186 Sanofi: R&D, 2015-2023 (US$ Million, AGR %)
Figure 187 Takeda Pharmaceuticals: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 188 Takeda Pharmaceuticals: R&D, 2015-2023 (US$ Million, AGR %)
Figure 189 UniQure NV: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 190 UniQure NV: R&D, 2015-2023 (US$ Million, AGR %)
Figure 191 Voyager Therapeutics: Net Revenue, 2015-2023 (US$ Million, AGR %)
Figure 192 Voyager Therapeutics: R&D, 2015-2023 (US$ Million, AGR %)

Companies Mentioned

American Gene Technologies
Applied Genetic
Astellas Pharma Inc.
Bayer
Benitec BioPharma
Biogen
Bluebird Bio
Bristol Myers Squibb
Calimmune, Inc. (CSL Behiring)
Cellectis
GeneQuine Biotherapeutics
GenSight Biologics
Gilead Lifesciences, Inc.
Novartis AG
Ocugen, Inc.
Orchard Therapeutics
Oxford Biomedica
Pfizer, Inc.
REGENXBIO Inc.
Sangamo Therapeutics, Inc.
Sanofi
Sarepta Therapeutics, Inc.
Spark Therapeutics (Subsidiary of Roche)
Takeda Pharmaceuticals
Taysha GTx
Transgene
UniQure N. V.
ViGeneron
Voyager Therapeutics
2seventy bio, Inc.
AmerisourceBergen
ABL Europe SAS
Ascend Advanced Therapies
Asklepios BioPharmaceutical, Inc.
Atamyo Therapeutics
Aurealis Therapeutics
Autolus Therapeutics plc
BlueRock Therapeutics LP
Cabaletta Bio, Inc.
CANbridge Pharmaceuticals Inc.
Cellares
Coave Therapeutics
Cytonus Therapeutics
Decibel Therapeutics, Inc.
Encellin
Encoded Therapeutics
Exothera S.A.
FUJIFILM Diosynth Biotechnologies
Gadeta B.V.
Genprex, Inc.
Hercules Capital, Inc.
Inhibrx, Inc.
INVO Bioscience
Immatics N.V.
Kadans Science Partner
Karuna Therapeutics, Inc.
Kriya Therapeutics, Inc.
Lexeo Therapeutics, Inc.
Liminal BioSciences, Inc.
MeiraGTx Holdings plc
Miltenyi Biotec
MorphoSys AG
Mytos
NAYA Biosciences
Neurocrine Biosciences, Inc.
Nvelop Therapeutics
Pacira BioSciences, Inc.
PTC Therapeutics, Inc.
Reata Pharmaceuticals, Inc.
Selecta Biosciences
Shinobi Therapeutics
Sio Gene Therapies
Syncona
Taysha Gene Therapies, Inc.
Tome Biosciences
T-Therapeutics
ViaNautis Bio
VectorBuilder
VectorY Therapeutics
Verve Therapeutics, Inc.
Vivet Therapeutics
Xbiome
Xcell Biosciences, Inc.
China’s National Medical Products Administration (NMPA)
Committee for Medicinal Products for Human Use (CHMP)
European Commission (EC)
European Medicines Agency (EMA)
Gene Therapy Net
Informa UK Limited
Journal of General Virology
Ministry of Health, Labour and Welfare (MHLW)
National Center for Biotechnology Information
The Alliance for Regenerative Medicine
The Royal Society
US Food and Drug Administration (FDA)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5471EUR$5,749USD£4,350GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6477EUR$6,806USD£5,150GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7609EUR$7,996USD£6,050GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9615EUR$10,104USD£7,645GBP